Guangzhou, China – 04 Sep 2026 – The Guangdong Provincial Drug Trading Center announced a special province‑wide survey targeting all medical institutions participating in the “Three Entry” (三进) channels for centrally procured drugs — grassroots public healthcare providers, medical‑insurance‑designated private institutions, and designated retail pharmacies — to gather data on procurement status, demand forecasts, supplier relationships, and financial‑service needs ahead of the program’s full rollout.
Policy Milestone
| Item | Detail |
|---|---|
| Issuing Authority | Guangdong Provincial Drug Trading Center |
| Policy Basis | Notice of the Guangdong Provincial Healthcare Security Administration on Promoting the Entry of Centrally Procured Drugs into Grassroots Medical Institutions, Private Medical Institutions and Retail Pharmacies (Yue Yi Bao Han [2025] No. 208) |
| Initiative | “Three Entry” (三进) program — bringing volume‑based procurement (VBP) drugs to grassroots, private and retail channels |
| Notice Date | 4 Sep 2026 |
| Submission Deadline | 30 Sep 2026 |
| Filing Method | Online questionnaire via QR code in the announcement — completed by the institution head or procurement lead |
| Support Channels | Hotline 020‑38302291; WeChat 19102021272 (weekdays 8:30–12:00, 14:00–17:30) |
Survey Scope & Coverage
- Public Grassroots Institutions: Township health centers, eligible community health service centers/stations, village clinics, and comparable primary‑care providers legally established and in normal operation within Guangdong.
- Private Medical Institutions: Facilities designated under the medical‑insurance system.
- Retail Pharmacies: Medical‑insurance‑designated drugstores, including both standalone and chain pharmacies.
- Data Collected: Current procurement practices, procurement demand forecasts, existing procurement relationships, and financial‑service needs across all three channels.
Participation & Data Use
- Filing Obligation: Institutions are asked to complete the Guangdong Province Centralized Drug Procurement “Three Entry” Project Questionnaire truthfully and accurately, reflecting actual operating conditions.
- Purpose Limitation: Submitted information will be used only to optimize the provincial platform’s implementation plan for the “Three Entry” program, improve the procurement and supply‑chain service system, and deliver precision matchmaking services between channels and suppliers.
- Deadline Discipline: The questionnaire closes on 30 Sep 2026; no extensions were mentioned in the notice.
Market Impact & Outlook
- Extending VBP Beyond Public Hospitals: The “Three Entry” program pushes centrally procured, price‑compressed drugs down into primary care, private clinics, and retail pharmacies — significantly widening the reachable market for winning bidders in national and Guangdong provincial procurement rounds.
- Data‑Driven Rollout: By first mapping demand forecasts and supply relationships channel‑by‑channel, Guangdong is signaling a precision‑implementation approach rather than a blanket mandate — survey results will likely shape distribution rules, platform workflows, and possibly channel‑specific financing support.
- Strategic Signal for Suppliers and Distributors: Pharmaceutical manufacturers and distributors should treat the 30 Sep deadline as an early‑warning indicator: institutions that participate will be better positioned in subsequent matchmaking, and the survey footprint previews where VBP drug flow will be steered next.
- Retail Channel Watch: Inclusion of chain and standalone pharmacies aligns with the national healthcare‑security agenda of routing VBP savings to outpatient and OTC‑adjacent settings — a structural shift for retail drug pricing in China’s largest provincial pharmaceutical market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation timeline, survey outcomes, and channel‑expansion plans of Guangdong’s “Three Entry” program for centrally procured drugs. Actual results may differ due to risks including participation rates, subsequent policy directives from provincial healthcare‑security authorities, supply‑chain capacity, and platform execution.-China Health Reform Pulse
Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2096765545348075520